Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Conditions
Interventions
Dasatinib
Locations
1
China
Xin Du
Shenzhen, Guangdong, China
Start Date
December 1, 2019
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2023
Last Updated
July 27, 2022
NCT06994676
NCT06523556
NCT06236724
NCT04195633
NCT07224100
NCT05334069
Lead Sponsor
Shenzhen Second People's Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions